Globus Medical (GMED), Why Is The Story Getting More Complicated?

Globus Medical (GMED) drew investor attention after its recent share move. The stock closed at US$75.60, with performance mixed over the past month and past 3 months, despite a higher 1 year total return.

For Globus Medical, the recent 1 day share price gain of 1.60% and a higher 1 year total shareholder return of 25% sit alongside a weaker year to date share price return. This suggests that long term holders have experienced stronger momentum than shorter term traders.

Scan Globus Medical's mixed momentum against a curated field of peers by comparing it with list of solid balance sheet and fundamentals (26 results) that have already attracted sustained institutional attention.

Globus Medical now trades at a sizeable discount to both analyst targets and estimated intrinsic value after a soft year to date share performance. Is that discount caution well earned or overly harsh?

Most Popular Narrative: 27% Undervalued

On the most followed narrative, Globus Medical screens as undervalued, with a fair value estimate of $103.23 against the last close at $75.60. That gap rests on how investors view its margin structure and installed robotics base.

Analysts expect Globus Medical to keep using its Excelsius robotics ecosystem and broader musculoskeletal platform to support higher margins and stronger differentiation in digital and implant driven healthcare workflows.

The main thing that has to go right is continued execution on margin expansion from manufacturing efficiencies and M&A synergies, while keeping growth on track in robotics, trauma, international spine and neuromodulation despite volatility in Enabling Technologies and Nevro revenue.

See why 20 investors see Globus Medical as 27% undervalued.

Result: Fair Value of $103.23 (UNDERVALUED)

Still, the Globus Medical story could be knocked off course if Enabling Technologies revenue volatility persists, or if Nevro’s reset continues to drag on profitability.

Find out about the key risks to this Globus Medical narrative.

Next Steps

Sentiment around Globus Medical is split. This is exactly why the next move belongs to you. Act while the data is fresh and weigh both risks and potential 5 key rewards

Looking for more investment ideas beyond Globus Medical?

If you stop with Globus Medical, you only see one angle on the market. Broaden your watchlist now and give yourself more ways to put your capital to work.

• Target potential mispricings by scanning a focused set of quality candidates through the 31 high quality undervalued stocks.
• Prioritise resilience by filtering for businesses with strong finances using the 31 resilient stocks with low risk scores.
• Get ahead of the crowd by searching for underfollowed opportunities in the 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com